Radiopharm Theranostics
RADXMelbourne, Australia· Est.
RAD develops innovative radiopharmaceuticals to deliver precision oncology diagnostics and therapies.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
RAD develops innovative radiopharmaceuticals to deliver precision oncology diagnostics and therapies.
Oncology
Technology Platform
Proprietary radiopharmaceutical platform using antibodies, nanobodies, peptides and small‑molecule ligands conjugated to therapeutic or diagnostic radioisotopes for precision oncology.
Opportunities
First‑in‑class B7H3 targeting could capture unmet oncology market share; dual‑listing provides capital flexibility for pipeline expansion.
Risk Factors
Clinical failure or delays in early‑stage trials; reliance on isotope supply chain; competition from larger radiopharmaceutical developers.
Competitive Landscape
Competes with established radiopharmaceuticals like Lutathera and emerging theranostic firms, but differentiates through novel antigen selection and integrated diagnostic‑therapeutic platform.